SEC EDGARAUG 141 min read$CGEM

Michaelson Jennifer sold $608K of CGEM

Michaelson Jennifer (Chief Scientific Officer) sold 30,000 shares of Cullinan Therapeutics, Inc. (CGEM) at $20.26 ($0.61M total) on 2026-08-13 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Michaelson Jennifer

Published Aug 14, 2026, 9:00 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 14, 2026, 9:09 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefInsider activity

Primary signal

$CGEM

Neutral

medium confidence

Mentioned

$CGEM

Relevance

4/10

alphai data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$CGEMNeutralLow

Why it matters

The newest disclosed fact is the CSO’s sale details (30,000 shares at $20.2600) and that it was executed under a pre-arranged 10b5-1 plan.

Market read

Traders may monitor insider activity for sentiment, but this specific disclosure lacks fundamental catalysts.

What to watch

The filing does not indicate whether other insiders or the company have concurrent news; without that, the signal is mostly sentiment.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-14, sale dated 2026-08-13

Background

The article is a SEC Form 4 insider transaction disclosure for Cullinan Therapeutics, Inc.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CGEMNeutralMedium confidence

Context

Cullinan Therapeutics CSO Jennifer Michaelson filed a Form 4 selling 30,000 shares at $20.2600 on 2026-08-13 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing discloses transaction size and price, but provides no new company fundamentals, guidance, or regulatory/operational catalyst.

Market effects

Sector

No clear sector read-through from a single 10b5-1 insider sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

10b5-1 sales can reflect routine liquidity planning rather than bearish expectations, so the market may ignore it.

Key entities

issuer
Cullinan Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
insider
Jennifer Michaelson
Chief Scientific Officer who sold shares.

Read at source ← All news

AUG 22

$CGEMMedAI 8/10

Why Cullinan Therapeutics (CGEM) Is Up 6.6% After Zipalertinib’s Positive Phase 3 Lung Cancer Data And What's Next

Cullinan Therapeutics (CGEM) shares rose 6.6% after positive Phase 3 trial results for zipalertinib in lung cancer. The trial met its primary endpoint, showing significant progression-free survival benefits. This positions zipalertinib as a potential first-line treatment for a specific subset of non-small cell lung cancer patients, supporting planned U.S. regulatory filings. Cullinan Therapeutics has no revenue but holds a high-risk pipeline with potential in oncology and autoimmune diseases.

simplywall.st3 min

AUG 21

$CGEMMedAI 9/10

Tokyo’s Taiho and Cullinan Announce Positive Phase 3 Lung Cancer Results

Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics (CGEM) reported positive Phase 3 trial results for zipalertinib in lung cancer. The trial met its primary endpoint, showing significant improvement in progression-free survival for patients with EGFR exon 20 insertion mutations. The companies plan to submit full results for presentation at an upcoming medical conference and pursue U.S. regulatory approval. Zipalertinib would compete with Johnson & Johnson's amivantamab (Rybrevant) i

geneonline.com2 min

AUG 20

$CGEMMedAI 8/10

Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer

Taiho Oncology and Cullinan Therapeutics (CGEM) announced that Phase 3 REZILIENT3 trial data for zipalertinib plus chemotherapy in EGFR exon 20 insertion mutation NSCLC will be presented at the 2026 IASLC World Conference. The trial met its primary endpoint of progression-free survival. Zipalertinib is an investigational EGFR inhibitor.

biospace.com2 min

AUG 13

$CGEMHighAI 8/10

Why is Cullinan Oncology stock surging today?

Cullinan Oncology (CGEM) shares rose about 6.4% pre-open after the company and partners reported REZILIENT3 Phase 3 results for zipalertinib plus platinum chemo in previously untreated EGFR exon 20 insertion NSCLC. The interim analysis met the primary endpoint with improved progression-free survival. The data supports U.S. first-line approval efforts, with up to $130M in milestones under the Cullinan-Taiho deal and a ~$334.5M cash balance.

investing.com4 min

AUG 6

$CGEMMed

Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Cullinan Therapeutics (Nasdaq: CGEM) reported Q2 2026 results and a corporate update. It said CLN-978 multi-dose data are planned for Q3 2026 (RA) and Q4 2026 (SLE), with Phase 2 expansions starting early 2027. CLN-049 Phase 2 in relapsed/refractory AML is planned for Q3 2026. Cash was $356.0M at June 30, 2026; net loss was $53.7M.

finanznachrichten.de6 min